Immunomodulatory properties of angiogenic factors and myeloid suppressor cells: a role in the gestational process
https://doi.org/10.25789/YMJ.2022.78.30
Abstract
The review presents data on the immunomodulatory role of angiogenic factors and myeloid suppressor cells. The mechanisms that play a key role in shaping the balance of proangiogenic and antiangiogenic factors, the role of endothelial growth factor (VEGF), placental growth factor (PlGF) and myeloid suppressor cells (MDSC, MS) in the development of gestational immunosuppression are shown. Data are presented on the molecular mechanisms of immunosuppression, the expression of check-point molecules that play a major role in the suppression of cellular immunity reactions. The role of tyrosine kinase receptors for proteins of the VEGF family - VEGF-1 (Flt-1), VEGFR-2 (KDR/Flk-1) in the regulation of immune responses has been characterized. Data are presented on the cross-regulatory interaction of angiogenic factors and myeloid suppressor cells and the immunomodulatory effect on cellular immunity responses. Disturbance of these mechanisms may be associated with the development of gestational complications, in particular preeclampsia. Based on the presented data, the possibility of evaluating VEGF and MS in pregnant women as prognostic biomarkers of preeclampsia is considered.
About the Authors
N. A. Khonina
Institute of Fundamental and Clinical Immunology; Novosibirsk State University
Russian Federation
Russian Federation
Khonina Natalia A. – M.D., leading researcher, laboratory of cellular immunotherapy; professor of Institute of Medicine and Psychology
Novosibirsk
A. V. Fedorova
Institute of Fundamental and Clinical Immunology, embryologist of Clinic Pasman
Russian Federation
Russian Federation
Fedorova Anastasia V. - intern
Novosibirsk
E. A. Smetanenko
Institute of Fundamental and Clinical Immunology, embryologist of Clinic Pasman
Russian Federation
Russian Federation
Smetanenko Ekatarina A. - post-graduate student, laboratory of cellular immunotherapy
Novosibirsk
N. M. Pasman
Novosibirsk State University
Russian Federation
Russian Federation
Pasman Natalia M. –M.D., head of Department of Obstetrics and Gynecology of Institute of Medicine and Psychology
Novosibirsk
E. R. Chernykh
Institute of Fundamental and Clinical Immunology
Russian Federation
Russian Federation
Chernykh Elena R. – M.D., professor, Corresponding Member of the Russian Academy of Sciences, head of laboratory of cellular immunotherapy
Novosibirsk
References
1. Strizhakov A.N., Timokhina E.V., Pitskhelauri E.G. [et al.]. Preeclampsia today: pathogenesis and possibilities of prediction and treatment Issues of gynecology, obstetrics and perinatology. 2016;15( 3): 24-31.
2. Chernykh E.R., Leplina O.Yu., Tikhonova M.A. [et al.]. Vascular endothelial growth factor receptor-1 signaling as a novel mechanism of t cell suppression in tumor neoangiogenesis. Medical Immunology. 2019; 21(4): 653-660.]
3. Smetanenko E.A., Leplina O.Yu., Tikhonova M.A. [et al.]. Placental growth factor modulates the response of in vitro activated T cells. Bulletin of Siberian Medicine.2020;19(4): 158-166.] doi: 10.20538/1682-0363-2020-4-158-166.
4. Angiogenic Marker Prognostic Models in Pregnant Women With Hypertension / Perry H., Binder J., Kalafat E. [et al.] // Hypertension.- 2020.-V.75.-P. 755–761
5. Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment / N. Horikawa, K. Abiko, N. Matsumura [et al.] // Br J Cancer. 2020-V. 122(6).-P.778-788. doi: 10.1038/s41416-019-0725-x.
6. Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia / I.C. Weel, R.N. Baergen, M. Romão-Veiga [et al.] // PLOS ONE.- 2016.- V. 11, № 6.
7. Bergenfelz C. The Generation and Identity of Human Myeloid-Derived Suppressor Cells / Bergenfelz C., Leandersson K.// Front. Oncol.-2020.-V. 10: 109. doi.org/10.3389/fonc.2020.00109.
8. Binding of the placental growth factor to VEGF receptor type 1 modulates human T cell functions / O.Yu. Leplina, E. Smetanenko, M. Tikhonova [et al.] //J Leukoc Biol.- 2020-V.108.-P.1013-1024. doi: 10.1002/JLB.2A0420-723RR
9. Circulating levels of angiogenic factors and their association with preeclampsia among pregnant women at Mulago National Referral Hospital in Uganda / Nabweyambo S., Sande O.J., McGovern N. [et al.] // PLOS ONE.-2021. doi. org/10.1371/ journal. pone. 0251227.
10. Circulating soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor during pregnancy in normotensive women in KwaZulu-Natal, South Africa / M. Ogunlola, P. Reddy, M.N. Sibiya [et al.] // Afr Health Sci.- 2019.- V. 19.-P.1821-1832.
11. Continuous activation of polymorphonuclear myeloid-derived suppressor cells during pregnancy is critical for fetal development ./ Shi M., Chen Z,. Chen M. [et al.] // Cell Mol Immunol.- 2021.-V.18 (7).-P.1692-1707. doi: 10.1038/s41423-021-00704-w
12. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment / Bourhis M., Palle J., Galy-Fauroux I. [et al.] //Front Immunol.- 2021.-12:616837.doi. org/10.3389/ fimmu. 2021. 616837.
13. Gabrilovich D.I. /Myeloid-derived suppressor cells / D.I. Gabrilovich//Cancer Immunol Res.- 2017.- V. 5, N. 1.- P. 3-8. doi:10.1158/2326-6066. CIR-16-0297.
14. Gardner A. Dendritic cells and cancer immunity / A. Gardner, B. Ruffell// Trends Immunol. - 2016.- V. 37.- P. 855–65.
15. Granulocytic Myeloid-Derived Suppressor Cells Accumulate in Human Placenta and Polarize toward a Th2 Phenotype / N. Kostlin, K.Hofstadter, A.L. Ostermeir [et al.] //J Immunol.- 2016.-V.196(3).-P.1132–45. doi: 10.4049/jimmunol.1500340.
16. Immature CD11b + Gr1+ myeloid cells that acquire immunosuppressive capability, also known as myeloid-derived suppressor cells (MDSCs), are a heterogeneous population of cells that regulate immune responses / M.P. Udumula, S. Sakr, S. Dar [et al.] // MolMetab.- 2021.- 53:101272. doi: 10.1016/j.molmet.2021.101272.
17. Jim B. Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications / B.Jim, S.A. Karumanchi // Semin Nephrol. - 2017.- V. 37.-P. 386–397.
18. Kostlin-Gille N. Myeloid-Derived Suppressor Cells in Pregnancy and the Neonatal Period / N.C. Kostlin-Gille N, C.Gille // Front. Immunol.- 2020.-V.11, 584712.
19. Kowalska W. Monocytic MDSC as a source of immunosuppressive cytokines in chronic lymphocytic leukemia (CLL) microenvironment / W. Kowalska, A. Bojarska-Junak // Folia HistochemCytobiol.- 2020.-V. 58 (1).-P.25-36. doi: 10.5603/FHC.a2020.0006.
20. Lecarpentier E. Angiogenic balance (sFlt-1/PlGF) and preeclampsia / E. Lecarpentier, V. Tsatsari // Ann Endocrinol.- 2016.- V. 77.- P. 97-100.
21. Maternal Serum Angiogenic Factor sFlt-1 to PlGF Ratio in Preeclampsia: A Useful Marker for Differential Diagnosis and Prognosis Evaluation in Chinese Women / W-Z. Lou, F. Jiang, J. Hu [et al.] // Dis Markers.- 2019:6270187–.10.1155/2019/6270187.
22. Mellor A.L. Indoleamine 2,3-Dioxygenase and Tolerance: Where Are We Now? /A.L. Mellor, H. Lemos, L.Huang // Front. Immunol.- 2017.- https:// doi.org/10.3389/fimmu. 2017.01360.
23. Ming Y. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment / Y. Ming, J. Dechao, Q. Shuang // Mol Cancer.- 2019.- V. 18, 60.
24. Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression / L. Albonici, M.G. Giganti, A. Modesti [et al.] // Int J Mol Sci.- 2019.-V. 20(12).-P. 2970. doi: 10.3390/ijms20122970
25. Myeloid-derived suppressor Cells (MDSC): When good intentions go awry./ Sanchez-Pino M.D., Dean M.J., A.C. Ochoa // Cell Immunol. - 2021.- V. 362:104302/ doi: 10.1016/j.cellimm.2021. 104302.
26. Pawelec G. Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity / G. Pawelec, C.P. Verschoor, S. Ostrand-Rosenberg // Front Immunol. – 2019.- V.10:1099. doi: 10.3389/ fimmu.2019.01099.
27. PlGF Immunological Impact during Pregnancy./Albonici L, Benvenuto M, Focaccetti C. [et al.] // Int J Mol Sci.- 2020.-V. 21(22):8714. doi: 10.3390/ijms21228714.
28. Roskoski R.Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas / R. Roskoski // Pharmacol Res.- 2017.- V.120.-P. 116–132.
29. Tesi R.J. MDSC; the Most Important Cell You Have Never Heard Of. /R.J. Tesi // Trends Pharmacol Sci.- 2019.- 40(1).-P.4-7. doi: 10.1016/j.tips.2018.10.008.
30. Limagne E., Richard C., Marion Thibaudin M. [et al.]. Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology.- 2019.-V. 8(4): e1564505 doi: 10.1080/2162402X. 2018.1564505.
31. Ullah К. Hypoxia-Inducible Factor Regulates Endothelial Metabolism in Cardiovascular Disease / K. Ullah, R. Wu // Front Physiol.- 2021.- V. 12: 670653. Published online 2021 Jul 5. doi: 10.3389/fphys. 2021.670653.
32. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis / C.S. Melincovici, A.B. Boşca, S. Şuşman [et al.]// Rom J Morphol Embryol.- 2018.- V. 59.- P. 455-467.
33. Yadav L. Tumour Angiogenesis and Angiogenic Inhibitors: A Review / L.Yadav //J clindiagn res. – 2015.- V. 9.- P.XE01-XE05.
34. Yang J. Targeting VEGF/VEGFR to Modulate Antitumor Immunity / J. Yang, J. Yan, B. Liu // Front. Immunol.- 2018.- V.9.- P. 978.
Review
For citations:
Khonina N.A., Fedorova A.V., Smetanenko E.A., Pasman N.M., Chernykh E.R. Immunomodulatory properties of angiogenic factors and myeloid suppressor cells: a role in the gestational process. Yakut Medical Journal. 2022;(2):117-120. https://doi.org/10.25789/YMJ.2022.78.30
Views:
21
Email this article 